My oncology practice is focused on genitourinary and gastrointestinal cancers. I am the site principal investigator of the Alliance 031701 Clinical Trial. In this trial we are looking at whether or not patients with bladder cancer who have a mutation in a DNA Damage Response (DDR) gene can avoid having to have their bladder surgically removed, which is currently the standard of care after chemotherapy. At the UF Health Cancer Center, I also manage patients with neuroendocrine tumors. We have recently brought to our center a new treatment known as Lutathera, which uses a radioactive isotope Lu-177 attached to a peptide called dotatate that specifically targets the cancer cells. My main goal is to bring new treatments and new clinical trials to the UF Health Cancer Center in order to better serve our patients.

In oncology, it seems like every day there is something new being discovered, which is great for our patients because it’s leading to new and better treatments. The field of immuno-oncology has really taken off over the past few years so I’m very excited about new treatments for cancer where we can possibly avoid chemotherapy.

My wife and I are avid runners and we enjoy doing half-marathons. Traveling is also something we enjoy, and we try to visit somewhere new every year.